Relutrigine

Relutrigine
Clinical data
Other namesPRAX-562; PRAX562
Routes of
administration		Oral[1]
Drug classSodium channel blocker; Anticonvulsant
Identifiers
  • 3-[ethoxy(difluoro)methyl]-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]-[1,2,4]triazolo[4,3-a]pyrazine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC15H11F6N5O2
Molar mass407.276 g·mol−1
3D model (JSmol)
  • CCOC(C1=NN=C2N1C=C(N=C2)C3=CC(=C(N=C3)OCC(F)(F)F)F)(F)F
  • InChI=1S/C15H11F6N5O2/c1-2-28-15(20,21)13-25-24-11-5-22-10(6-26(11)13)8-3-9(16)12(23-4-8)27-7-14(17,18)19/h3-6H,2,7H2,1H3
  • Key:BFXBSYMVTNEFRF-UHFFFAOYSA-N

Relutrigine (INNTooltip International Nonproprietary Name; developmental code name PRAX-562) is a persistent neuronal sodium channel blocker which is under development for the treatment of epilepsy and headache.[1][2][3] It is taken orally.[1] The drug shows anticonvulsant effects in animals but with improved tolerability compared to existing sodium channel blockers.[2][3] Relutrigine is under development by Praxis Precision Medicines.[1][2] As of May 2026, it is in preregistration for epilepsy.[1] Conversely, no recent development has been reported for headaches.[1]

See also

References

  1. ^ a b c d e f "Praxis-Precision-Medicines". AdisInsight. 19 May 2026. Retrieved 6 June 2026.
  2. ^ a b c Müller P, Draguhn A, Egorov AV (October 2024). "Persistent sodium currents in neurons: potential mechanisms and pharmacological blockers". Pflugers Archiv. 476 (10): 1445–1473. doi:10.1007/s00424-024-02980-7. PMC 11381486. PMID 38967655.
  3. ^ a b Kahlig KM, Scott L, Hatch RJ, Griffin A, Martinez Botella G, Hughes ZA, et al. (March 2022). "The novel persistent sodium current inhibitor PRAX-562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers". Epilepsia. 63 (3): 697–708. doi:10.1111/epi.17149. PMC 9304232. PMID 35037706.
Stub icon

This anticonvulsant-related article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.